NCT02139995

Brief Summary

Guidelines for blood transfusion have been issued for years. According to these guidelines, red blood cells (RBCs) transfusion should be given when the hemoglobin level is less than 6g/dL or 7g/dL and is unnecessary when the level is more than 10g/dL. However, in all the guidelines, the determination of whether RBCs should be administered when the hemoglobin level is in the range of 6\~10g/dL is based on the judgment from doctors. Index of transfusion trigger for patients with hemoglobin level between 6g/dL and 10g/dL is necessary and important in clinical practice. Based on the aim of blood transfusion that maintain the balance of oxygen supply and oxygen consumption, the investigators hypothesize that index of transfusion trigger for patients with hemoglobin level between 6g/dL and 10g/dL could be calculated by parameters including infusion rate of inotropic drugs for maintaining normal cardiac output, fraction of inspired oxygen, core temperature, and torlerance to anemia. To verify this hypothesis, the investigators present West China Transfusion Score for Critically-ill Patients(WCTS-CP) for the trigger of transfusion according to the patient's history and monitoring parameters, and the investigators design a randomized controlled clinical trial to test this score.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started May 2014

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2014

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

May 11, 2014

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 16, 2014

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2014

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2014

Completed
Last Updated

May 16, 2014

Status Verified

May 1, 2014

Enrollment Period

4 months

First QC Date

May 11, 2014

Last Update Submit

May 13, 2014

Conditions

Keywords

transfusiontriggercritically-ill

Outcome Measures

Primary Outcomes (1)

  • Incidence of death and serious complications

    28 days

Secondary Outcomes (3)

  • Transfusion rate and transfusion volume of red blood cells

    28 days

  • ventilator-free days in 28 days

    28 days

  • length of stay in ICU or in hospital

    28 days

Study Arms (2)

Transfusion trigger based on WCTS-CP

EXPERIMENTAL

Determination of whether a patient need red blood cells transfusion or which hemoglobin level should be maintained is based on WCTS-CP

Behavioral: RBC transfusion based on different protocols

Transfusion trigger based on experience

ACTIVE COMPARATOR

Determination of whether a patient need red blood cell transfusion or which hemoglobin level should be maintained is base on the physician's experience

Behavioral: RBC transfusion based on different protocols

Interventions

transfusion trigger for experimental group is the WCTS-CP;for active comparator is the physician's experience

Transfusion trigger based on WCTS-CPTransfusion trigger based on experience

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Height of usual place of residence less than 2,500 metres above sea level
  • Hemoglobin level possibly less than 10g/dL

You may not qualify if:

  • Pregnant women
  • Age less than 18
  • Serious blood system diseases
  • Dysfunction of hemoglobin
  • Tumor metastasis
  • Psychopathy
  • Refuse to sign consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

West China Hospital

Chengdu, Sichuan, 610041, China

Location

MeSH Terms

Conditions

Critical Illness

Condition Hierarchy (Ancestors)

Disease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Jin Liu, M.D

    West China Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jin Liu, M.D

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
ICU

Study Record Dates

First Submitted

May 11, 2014

First Posted

May 16, 2014

Study Start

May 1, 2014

Primary Completion

September 1, 2014

Study Completion

December 1, 2014

Last Updated

May 16, 2014

Record last verified: 2014-05

Locations